Huiyu Pharmaceutical (688553.SH): The first subject in the HY-2003 Phase I clinical trial received the drug.

HuYu Pharmaceuticals (688553.SH) announced that the company's independently developed drug HY-2003 is undergoing Phase I clinical trials for the treatment of excessive submental fat accumulation in a recent population. The first subject has successfully received the drug. HY-2003 is a new drug of chemical category 2.2 with improvements, intended to improve moderate to severe contour protrusion caused by submental fat accumulation in adults. The clinical trial application for this product was accepted by the Drug Evaluation Center of the National Medical Products Administration in September 2024 (acceptance number CHXL2400928), and in November 2024, the company received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration (notification number: 2024LP02644). Recently, the company successfully completed the first subject's dosing for the Phase I clinical trial of HY-2003.